A citation-based method for searching scientific literature

Hans-Peter Hammes, Xueliang Du, Diane Edelstein, Tetsuya Taguchi, Takeshi Matsumura, Qida Ju, Jihong Lin, Angelika Bierhaus, Peter Nawroth, Dieter Hannak, Michael Neumaier, Regine Bergfeld, Ida Giardino, Michael Brownlee. Nat Med 2003
Times Cited: 536







List of co-cited articles
1134 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.
Roya Babaei-Jadidi, Nikolaos Karachalias, Naila Ahmed, Sinan Battah, Paul J Thornalley. Diabetes 2003
255
19

Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose.
Elena Berrone, Elena Beltramo, Carmela Solimine, Alessandro Ubertalli Ape, Massimo Porta. J Biol Chem 2006
100
16

Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
H Stracke, W Gaus, U Achenbach, K Federlin, R G Bretzel. Exp Clin Endocrinol Diabetes 2008
85
18


High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease.
P J Thornalley, R Babaei-Jadidi, H Al Ali, N Rabbani, A Antonysunil, J Larkin, A Ahmed, G Rayman, C W Bodmer. Diabetologia 2007
145
13



Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
W Kline Bolton, Daniel C Cattran, Mark E Williams, Sharon G Adler, Gerald B Appel, Kenneth Cartwright, Peter G Foiles, Barry I Freedman, Philip Raskin, Robert E Ratner,[...]. Am J Nephrol 2004
302
10

A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
H Stracke, A Lindemann, K Federlin. Exp Clin Endocrinol Diabetes 1996
93
10


Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.
Xiaoli Pan, Zhichun Chen, Guoqiang Fei, Shumei Pan, Weiqi Bao, Shuhua Ren, Yihui Guan, Chunjiu Zhong. Neurosci Bull 2016
28
35

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
T Nishikawa, D Edelstein, X L Du, S Yamagishi, T Matsumura, Y Kaneda, M A Yorek, D Beebe, P J Oates, H P Hammes,[...]. Nature 2000
10

Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.
Solomon Tesfaye, Andrew J M Boulton, Peter J Dyck, Roy Freeman, Michael Horowitz, Peter Kempler, Giuseppe Lauria, Rayaz A Malik, Vincenza Spallone, Aaron Vinik,[...]. Diabetes Care 2010
9



Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
Xiaoli Pan, Neng Gong, Jing Zhao, Zhe Yu, Fenghua Gu, Jia Chen, Xiaojing Sun, Lei Zhao, Meijing Yu, Zhiru Xu,[...]. Brain 2010
76
11

Diabetic Neuropathy: A Position Statement by the American Diabetes Association.
Rodica Pop-Busui, Andrew J M Boulton, Eva L Feldman, Vera Bril, Roy Freeman, Rayaz A Malik, Jay M Sosenko, Dan Ziegler. Diabetes Care 2017
707
9


Advanced glycation end products in foods and a practical guide to their reduction in the diet.
Jaime Uribarri, Sandra Woodruff, Susan Goodman, Weijing Cai, Xue Chen, Renata Pyzik, Angie Yong, Gary E Striker, Helen Vlassara. J Am Diet Assoc 2010
586
8

Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Thomas O Metz, Nathan L Alderson, Suzanne R Thorpe, John W Baynes. Arch Biochem Biophys 2003
134
8

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Dan Ziegler, Phillip A Low, William J Litchy, Andrew J M Boulton, Aaron I Vinik, Roy Freeman, Rustem Samigullin, Hans Tritschler, Ullrich Munzel, Joachim Maus,[...]. Diabetes Care 2011
198
8

Global prevalence and major risk factors of diabetic retinopathy.
Joanne W Y Yau, Sophie L Rogers, Ryo Kawasaki, Ecosse L Lamoureux, Jonathan W Kowalski, Toke Bek, Shih-Jen Chen, Jacqueline M Dekker, Astrid Fletcher, Jakob Grauslund,[...]. Diabetes Care 2012
8

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
M Brownlee, H Vlassara, A Kooney, P Ulrich, A Cerami. Science 1986
8



The multifaceted therapeutic potential of benfotiamine.
Pitchai Balakumar, Ankur Rohilla, Pawan Krishan, Ponnu Solairaj, Arunachalam Thangathirupathi. Pharmacol Res 2010
54
14

Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives.
Marie-Laure Volvert, Sandrine Seyen, Marie Piette, Brigitte Evrard, Marjorie Gangolf, Jean-Christophe Plumier, Lucien Bettendorff. BMC Pharmacol 2008
48
16



Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
Josephine M Forbes, Suzanne R Thorpe, Vicki Thallas-Bonke, Josefa Pete, Merlin C Thomas, Elizabeth R Deemer, Sahar Bassal, Assam El-Osta, David M Long, Sianna Panagiotopoulos,[...]. J Am Soc Nephrol 2005
169
7

Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy.
Angelika Bierhaus, Thomas Fleming, Stoyan Stoyanov, Andreas Leffler, Alexandru Babes, Cristian Neacsu, Susanne K Sauer, Mirjam Eberhardt, Martina Schnölzer, Felix Lasitschka,[...]. Nat Med 2012
319
7

The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial.
David A Fraser, Lien M Diep, Inger Anette Hovden, Kristian B Nilsen, Kari Anne Sveen, Ingebjørg Seljeflot, Kristian F Hanssen. Diabetes Care 2012
35
20


Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
7

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
B I Freedman, J P Wuerth, K Cartwright, R P Bain, S Dippe, K Hershon, A D Mooradian, B S Spinowitz. Control Clin Trials 1999
162
7

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.
N Rabbani, S S Alam, S Riaz, J R Larkin, M W Akhtar, T Shafi, P J Thornalley. Diabetologia 2009
99
7

Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.
Xueliang Du, Takeshi Matsumura, Diane Edelstein, Luciano Rossetti, Zsuzsanna Zsengellér, Csaba Szabó, Michael Brownlee. J Clin Invest 2003
537
7

Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells.
Marjorie Gangolf, Jan Czerniecki, Marc Radermecker, Olivier Detry, Michelle Nisolle, Caroline Jouan, Didier Martin, Frédéric Chantraine, Bernard Lakaye, Pierre Wins,[...]. PLoS One 2010
113
7

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
L Park, K G Raman, K J Lee, Y Lu, L J Ferran, W S Chow, D Stern, A M Schmidt. Nat Med 1998
930
6

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
K C B Tan, W S Chow, A W K Tso, A Xu, H F Tse, R L C Hoo, D J Betteridge, K S L Lam. Diabetologia 2007
68
8

Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
J L Wautier, C Zoukourian, O Chappey, M P Wautier, P J Guillausseau, R Cao, O Hori, D Stern, A M Schmidt. J Clin Invest 1996
456
6

Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.
M P Wautier, O Chappey, S Corda, D M Stern, A M Schmidt, J L Wautier. Am J Physiol Endocrinol Metab 2001
751
6


Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes.
Dan Ziegler, Erwin Schleicher, Alexander Strom, Birgit Knebel, Thomas Fleming, Peter Nawroth, Hans-Ulrich Häring, Nikolaos Papanas, Julia Szendrödi, Karsten Müssig,[...]. Diabetes Metab Res Rev 2017
12
50

Epidemiology of polyneuropathy in diabetes and prediabetes.
Dan Ziegler, Nikolaos Papanas, Aaron I Vinik, Jonathan E Shaw. Handb Clin Neurol 2014
102
6

Enhanced glucose control for preventing and treating diabetic neuropathy.
Brian C Callaghan, Ann A Little, Eva L Feldman, Richard A C Hughes. Cochrane Database Syst Rev 2012
265
6

Systematic review of treatments for diabetic peripheral neuropathy.
N Çakici, T M Fakkel, J W van Neck, A P Verhagen, J H Coert. Diabet Med 2016
61
9

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials.
Gerritje S Mijnhout, Boudewijn J Kollen, Alaa Alkhalaf, Nanno Kleefstra, Henk J G Bilo. Int J Endocrinol 2012
66
9




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.